Pharming Group AI Stock Analysis
Pharming Group (PHG) AI Stock Analysis
Pharming Group
(Frankfurt:PHG)
No summary available
Pharming Group (PHG) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 891.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 275
- Price to Earnings (P/E)
- 35.7
- Beta (1Y)
- 0.71
- Revenue Growth
- 1.73%
- EPS Growth
- ―
- Country
- Germany
- Employees
- 407
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Pharming Group Business Overview & Revenue Model
Company Description
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical need...
Pharming Group Earnings Call Summary
The call was predominantly positive, supported by 21% third-quarter revenue growth, 58% Joenja growth, RUCONEST's return to revenue growth and stabilized U.S. demand, an 89% increase in operating profit, improved full-year guidance, strong liquidity, pediatric and international expansion, and encouraging clinical progress. The main challenges were the expected approximately 3% full-year decline in RUCONEST U.S. revenue, inventory-related timing effects, manufacturing inventory impairments, the unresolved CEO search, and prior FALCON site-activation delays.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the full year 2026, revenue guidance was tightened to $380 million to $390 million, representing 14% growth, while operating expense guidance was lowered to $310 million to $315 million, representing 0% to 1% growth, including approximately $35 million incremental R&D investment and about $9 million of structural G&A savings; guidance assumes RUCONEST revenue will stabilize and return to growth in the second half of 26 and Joenja will deliver significant and accelerating growth, with RUCONEST U. S. Revenue expected to decline approximately 3% for the full year and Joenja annual revenue growth expected in the mid-30s%, while cost of goods sold is expected to be approximately 12% of revenue, corresponding to a gross margin of 88%, and Q4 revenue is implied to be roughly $100 million to $110 million; the company expects an initial bolus of new Joenja pediatric patients on therapy throughout Q4 in the range of 15 to 20 patients, expects 145 of the planned 180 FALCON participants to be enrolled by the end of this year, enrollment to be complete during the first half of 27, and top line results approximately 1 year after enrollment is complete, and expects to report top-line CVID results in November.
Pharming Group Risk Analysis
Pharming Group disclosed 63 risk factors in its most recent earnings report. Pharming Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskPharming Group Peers Comparison
Overall Rating
PLX77Outperform
RIGL73Outperform
ZVRA73Outperform
FENC66Neutral
XFOR43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $257.17M | 11.72 | 30.74% | ― | 36.96% | 266.67% | |
| 73Outperform | $837.18M | 2.64 | 73.94% | ― | 2.18% | 165.65% | |
| 73Outperform | $540.30M | 7.09 | 38.19% | ― | 75.10% | 103.22% | |
| 66Neutral | $410.25M | 507.42 | 4.92% | ― | 71.09% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $318.59M | -4.66 | -49.62% | ― | -50.08% | 93.36% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:PHG | Pharming Group Nv | 11.20 | 0.30 | 2.75% | |
| PLX | Protalix Biotherapeutics | 3.05 | 1.16 | 61.38% | |
| RIGL | Rigel Pharmaceuticals | 44.46 | 1.95 | 4.59% | |
| ZVRA | Zevra Therapeutics, Inc. | 9.08 | -0.10 | -1.09% | |
| FENC | Fennec Pharmaceuticals | 11.62 | 2.87 | 32.80% | |
| XFOR | X4 Pharmaceuticals | 3.12 | -0.54 | -14.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
